Tag - SOLY

Developments

FDA clears Soliton RAP technology for cellulite improvement

The FDA cleared Soliton’s (NASDAQ:SOLY) Rapid Acoustic Pulse (RAP) technology for the short-term improvement in the appearance of cellulite. Soliton’s rapid-pulsed technology safely and comfortably breaks apart the...

February 1, 2021

Executive Moves

Soliton appoints Brad Hauser as president, CEO

Brad Hauser Soliton (NASDAQ:SOLY) named Brad Hauser as president and CEO as the company prepares for its commercial launch. Mr. Hauser most recently was VP of R&D and general manager for CoolSculpting at Allergan...

November 2, 2020

Feature

Soliton seeking FDA okay to treat cellulite with Rapid Acoustic Pulse

Soliton (NASDAQ:SOLY) has filed a 510(k) submission for FDA clearance of its Rapid Acoustic Pulse (RAP) technology for reduction in the appearance of cellulite, which affects between 80% and 90% of women. The FDA has...

July 21, 2020

Developments

Soliton files 510(k) for RAP device approval to reduce cellulite

Soliton (NASDAQ:SOLY) filed for 510(k) premarket clearance with the FDA of its second generation Rapid Acoustic Pulse (RAP) device for the reduction in the appearance of cellulite. The 510(k) filing is based on results...

July 1, 2020

Developments

Soliton posts positive pivotal cellulite trial results

Soliton (NASDAQ:SOLY) presented new positive data from the company’s pivotal cellulite clinical trial at the American Academy of Dermatology 2020 virtual conference. The trial enrolled and treated 67 subjects at four...

June 15, 2020

Markets

Roth starts Soliton at buy; PT $14

Roth Capital Partners launched coverage of Soliton (NASDAQ:SOLY) with a “buy” rating and $14 price target. The stock closed at $8.80 on March 26. Soliton is an aesthetic company that utilizes acoustic pulse technology...

March 27, 2020

Tag - SOLY

FDA clears Soliton RAP technology for cellulite improvement

Soliton appoints Brad Hauser as president, CEO

Soliton seeking FDA okay to treat cellulite with Rapid Acoustic Pulse

Soliton files 510(k) for RAP device approval to reduce cellulite

Soliton posts positive pivotal cellulite trial results

Roth starts Soliton at buy; PT $14

General

More